Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$1.1 - $2.45 $4,436 - $9,880
4,033 Added 18.19%
26,207 $32,000
Q3 2022

Nov 14, 2022

BUY
$1.96 - $3.32 $16,863 - $28,565
8,604 Added 63.4%
22,174 $46,000
Q2 2022

Aug 15, 2022

BUY
$2.27 - $4.86 $7,268 - $15,561
3,202 Added 30.88%
13,570 $38,000
Q1 2022

May 16, 2022

BUY
$3.69 - $5.65 $38,257 - $58,579
10,368 New
10,368 $45,000
Q3 2021

Nov 15, 2021

SELL
$5.54 - $7.51 $249,549 - $338,287
-45,045 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$7.78 - $11.4 $49,403 - $72,390
6,350 Added 16.41%
45,045 $383,000
Q1 2021

May 17, 2021

BUY
$5.12 - $8.48 $10,291 - $17,044
2,010 Added 5.48%
38,695 $306,000
Q4 2020

Feb 16, 2021

BUY
$3.16 - $7.03 $115,924 - $257,895
36,685 New
36,685 $214,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.